Boehringer Ingelheim Initiaties Pivotal Trial on Volasertib* for Acute Myeloid Leukaemia
- ICU
- 06/03/2013
Boehringer Ingelheim invests in rare diseases with high unmet medical need. Volasertib* is in Phase III clinical development for acute myeloid leukaemia and nintedanib* is in Phase III clinical...
READ MORE